Oncothryreon snags $47M for early anticancers
This article was originally published in Scrip
Executive Summary
Oncothyreon, a clinical-stage biopharmaceutical company focusing on treatments for cancers, has raised $47 million from a stock offering, giving the company an additional 18 months worth of cash to advance its unpartnered assets.